The Experts below are selected from a list of 168 Experts worldwide ranked by ideXlab platform
Heidi Turunen - One of the best experts on this subject based on the ideXlab platform.
-
Cost-effectiveness of levoDOPA/carbiDOPA/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Current medical research and opinion, 2005Co-Authors: Leslie J Findley, Andrew J. Lees, Marjo Apajasalo, Anna Pitkänen, Heidi TurunenAbstract:ABSTRACTBackground and methods: A Markov model was developed to evaluate the cost-effectiveness of levoDOPA/carbiDOPA/entacapone (LCE;Stalevo*), in the treatment of patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (wearing-off). LCE, with or without other antiparkinsonian medications, was compared to UK standard care, comprising traditional levoDOPA/DOPA-Decarboxylase Inhibitor (DDCI) with other antiparkinsonian medications (e.g. selegiline or DOPAmine agonists) added as needed. The costs and outcomes of both treatments were projected over a period of 10 years from the perspective (a) of society as a whole and (b) of the UK National Health Service (NHS). Sensitivity analyses, including second-order Monte Carlo simulations, were performed to assess the confidence level of the primary results.Results: Treatment with LCE produced an average gain of +1.04 quality-adjusted life-years (QALYs) per patient (2.57 vs. 1.53) in the base-case analysis (discount rate 3.5%). This gain was accom...
-
cost effectiveness of levoDOPA carbiDOPA entacapone stalevo compared to standard care in uk parkinson s disease patients with wearing off
Current Medical Research and Opinion, 2005Co-Authors: Leslie J Findley, Andrew J. Lees, Marjo Apajasalo, Anna Pitkänen, Heidi TurunenAbstract:ABSTRACTBackground and methods: A Markov model was developed to evaluate the cost-effectiveness of levoDOPA/carbiDOPA/entacapone (LCE;Stalevo*), in the treatment of patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (wearing-off). LCE, with or without other antiparkinsonian medications, was compared to UK standard care, comprising traditional levoDOPA/DOPA-Decarboxylase Inhibitor (DDCI) with other antiparkinsonian medications (e.g. selegiline or DOPAmine agonists) added as needed. The costs and outcomes of both treatments were projected over a period of 10 years from the perspective (a) of society as a whole and (b) of the UK National Health Service (NHS). Sensitivity analyses, including second-order Monte Carlo simulations, were performed to assess the confidence level of the primary results.Results: Treatment with LCE produced an average gain of +1.04 quality-adjusted life-years (QALYs) per patient (2.57 vs. 1.53) in the base-case analysis (discount rate 3.5%). This gain was accom...
Leontino Battistin - One of the best experts on this subject based on the ideXlab platform.
-
Long‐term treatment of Parkinson's disease with L‐DOPA and DOPA‐Decarboxylase Inhibitor: Therapeutic results and side effects
Acta neurologica Scandinavica, 2009Co-Authors: Leontino Battistin, Giorgio Meneghetti, Simone Rigotti, Saia AAbstract:The authors present a review of their clinical experience in the treatment of 127 Parkinsonian patients with L-DOPA alone and in association with a DOPA-Decarboxylase Inhibitor; the follow-up lasted more than 7 years. In all cases the dosages of L-DOPA, either alone or associated with the Decarboxylase Inhibitor, were fairly low; the strategy was to reach in each case the minimal effective dose instead of the maximal tolerable one. After 7 years of treatment about 60–65 % of the patients had shown improvement, even though to a lesser degree than during the first and second year of therapy; the remaining 35–40 % were unchanged or worse. The authors conclude that, despite the decreased efficacy of the therapy with time, the L-DOPA treatment remains of great significance in lengthening and in improving the quality of life of Parkinsonian patients.
-
long term treatment of parkinson s disease with l DOPA and DOPA Decarboxylase Inhibitor therapeutic results and side effects
Acta Neurologica Scandinavica, 2009Co-Authors: Leontino Battistin, Giorgio Meneghetti, Simone Rigotti, A SaiaAbstract:The authors present a review of their clinical experience in the treatment of 127 Parkinsonian patients with L-DOPA alone and in association with a DOPA-Decarboxylase Inhibitor; the follow-up lasted more than 7 years. In all cases the dosages of L-DOPA, either alone or associated with the Decarboxylase Inhibitor, were fairly low; the strategy was to reach in each case the minimal effective dose instead of the maximal tolerable one. After 7 years of treatment about 60–65 % of the patients had shown improvement, even though to a lesser degree than during the first and second year of therapy; the remaining 35–40 % were unchanged or worse. The authors conclude that, despite the decreased efficacy of the therapy with time, the L-DOPA treatment remains of great significance in lengthening and in improving the quality of life of Parkinsonian patients.
Leslie J Findley - One of the best experts on this subject based on the ideXlab platform.
-
Cost-effectiveness of levoDOPA/carbiDOPA/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Current medical research and opinion, 2005Co-Authors: Leslie J Findley, Andrew J. Lees, Marjo Apajasalo, Anna Pitkänen, Heidi TurunenAbstract:ABSTRACTBackground and methods: A Markov model was developed to evaluate the cost-effectiveness of levoDOPA/carbiDOPA/entacapone (LCE;Stalevo*), in the treatment of patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (wearing-off). LCE, with or without other antiparkinsonian medications, was compared to UK standard care, comprising traditional levoDOPA/DOPA-Decarboxylase Inhibitor (DDCI) with other antiparkinsonian medications (e.g. selegiline or DOPAmine agonists) added as needed. The costs and outcomes of both treatments were projected over a period of 10 years from the perspective (a) of society as a whole and (b) of the UK National Health Service (NHS). Sensitivity analyses, including second-order Monte Carlo simulations, were performed to assess the confidence level of the primary results.Results: Treatment with LCE produced an average gain of +1.04 quality-adjusted life-years (QALYs) per patient (2.57 vs. 1.53) in the base-case analysis (discount rate 3.5%). This gain was accom...
-
cost effectiveness of levoDOPA carbiDOPA entacapone stalevo compared to standard care in uk parkinson s disease patients with wearing off
Current Medical Research and Opinion, 2005Co-Authors: Leslie J Findley, Andrew J. Lees, Marjo Apajasalo, Anna Pitkänen, Heidi TurunenAbstract:ABSTRACTBackground and methods: A Markov model was developed to evaluate the cost-effectiveness of levoDOPA/carbiDOPA/entacapone (LCE;Stalevo*), in the treatment of patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (wearing-off). LCE, with or without other antiparkinsonian medications, was compared to UK standard care, comprising traditional levoDOPA/DOPA-Decarboxylase Inhibitor (DDCI) with other antiparkinsonian medications (e.g. selegiline or DOPAmine agonists) added as needed. The costs and outcomes of both treatments were projected over a period of 10 years from the perspective (a) of society as a whole and (b) of the UK National Health Service (NHS). Sensitivity analyses, including second-order Monte Carlo simulations, were performed to assess the confidence level of the primary results.Results: Treatment with LCE produced an average gain of +1.04 quality-adjusted life-years (QALYs) per patient (2.57 vs. 1.53) in the base-case analysis (discount rate 3.5%). This gain was accom...
Saia A - One of the best experts on this subject based on the ideXlab platform.
-
Long‐term treatment of Parkinson's disease with L‐DOPA and DOPA‐Decarboxylase Inhibitor: Therapeutic results and side effects
Acta neurologica Scandinavica, 2009Co-Authors: Leontino Battistin, Giorgio Meneghetti, Simone Rigotti, Saia AAbstract:The authors present a review of their clinical experience in the treatment of 127 Parkinsonian patients with L-DOPA alone and in association with a DOPA-Decarboxylase Inhibitor; the follow-up lasted more than 7 years. In all cases the dosages of L-DOPA, either alone or associated with the Decarboxylase Inhibitor, were fairly low; the strategy was to reach in each case the minimal effective dose instead of the maximal tolerable one. After 7 years of treatment about 60–65 % of the patients had shown improvement, even though to a lesser degree than during the first and second year of therapy; the remaining 35–40 % were unchanged or worse. The authors conclude that, despite the decreased efficacy of the therapy with time, the L-DOPA treatment remains of great significance in lengthening and in improving the quality of life of Parkinsonian patients.
A Saia - One of the best experts on this subject based on the ideXlab platform.
-
long term treatment of parkinson s disease with l DOPA and DOPA Decarboxylase Inhibitor therapeutic results and side effects
Acta Neurologica Scandinavica, 2009Co-Authors: Leontino Battistin, Giorgio Meneghetti, Simone Rigotti, A SaiaAbstract:The authors present a review of their clinical experience in the treatment of 127 Parkinsonian patients with L-DOPA alone and in association with a DOPA-Decarboxylase Inhibitor; the follow-up lasted more than 7 years. In all cases the dosages of L-DOPA, either alone or associated with the Decarboxylase Inhibitor, were fairly low; the strategy was to reach in each case the minimal effective dose instead of the maximal tolerable one. After 7 years of treatment about 60–65 % of the patients had shown improvement, even though to a lesser degree than during the first and second year of therapy; the remaining 35–40 % were unchanged or worse. The authors conclude that, despite the decreased efficacy of the therapy with time, the L-DOPA treatment remains of great significance in lengthening and in improving the quality of life of Parkinsonian patients.